Involvement of tissue plasminogen activator in stress responsivity during acute cocaine withdrawal in mice

Stress

Volumn 13, Issue 6, 2010, Pages 481-490

  Zhou, Yan ^a   Maiya, Rajani ^a   Norris, Erin H ^a   Kreek, Mary Jeanne ^a   Strickland, Sidney ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

amygdala; cocaine withdrawal; CRF; HPA axis; tPA

Indexed keywords

COCAINE; CORTICOTROPIN RELEASING FACTOR; MESSENGER RNA; TISSUE PLASMINOGEN ACTIVATOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COCAINE DEPENDENCE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE DELETION; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; STRESS; WILD TYPE; WITHDRAWAL SYNDROME;

AMYGDALA; ANIMALS; COCAINE; CORTICOSTERONE; CORTICOTROPIN-RELEASING HORMONE; HIPPOCAMPUS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MICE; MICE, INBRED C57BL; PITUITARY-ADRENAL SYSTEM; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRO-OPIOMELANOCORTIN; RNA, MESSENGER; STRESS, PHYSIOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77958077550     PISSN: 10253890     EISSN: 16078888     Source Type: Journal    
DOI: 10.3109/10253891003786415     Document Type: Article

References (60)

1. Ambrosio E, Sharpe LG, Pilotte NS. 1997. Regional binding to corticotropin releasing factor receptors in brain of rats exposed to chronic cocaine and cocaine withdrawal. Synapse 25: 272-276.
2. Aouizerate B, Ho A, Schluger JH, Perret G, Borg L, Le Moal M, Piazza PV, Kreek MJ. 2006. Glucocroticoid negative feedback in methadone-maintained former heroin addicts with ongoing cocaine dependence: Dose-response to dexamethasone suppression. Addict Biol 11:84-96.
3. Back SE, Hartwell K, Desantis SM, Saladin M, McRae-Clark AL, Price KL, Moran-Santa Maria MM, Baker NL, Spratt E, Kreek MJ, Brady KT. 2010. Reactivity to laboratory stress provocation predicts relapse to cocaine. Drug Alcohol Depend 106:21-27.
4. Bahi A, Dreyer JL. 2008. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine-and morphine-induced reward and behavioral sensitization. Genes Brain Behav 7:244-256.
5. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. 1998. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 21:813-825.
6. Basso AM, Spina M, Rivier J, Vale W, Koob GF. 1999. Corticotropin- releasing factor antagonist attenuates the "anxiogenic-like" effect in the defensive burying paradigm but not in elevated plus-maze following chronic cocaine in rats. Psychopharmacology 145:21-30.
7. Baumann MH, Gendron TM, Becketts KM, Henningfield JE, Gorelick DA, Rothman RB. 1995. Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biol Psychiatry 38:751-755.
8. Befort K, Filliol D, Ghate A, Darcq E, Matifas A, Muller J, Lardenois A, Thibault C, Dembele D, Le Merrer J, Becker J, Poch O, Kieffer B. 2008. Mu-opioid receptor activation induces transcriptional plasticity in the central extended amygdala. Eur J Neurosci 27:2973-2984.
9. Borowsky B, Kuhn CM. 1991. Chronic cocaine administration sensitizes behavioral but not neuroendocrine responses. Brain Res 543:301-306.
10. Brady KT, McRae AL, Moran-Santa Maria MM, DeSantis SM, Simpson AN, Waldrop AE, Back SE, Kreek MJ. 2009. Response to corticotropin-releasing hormone infusion in cocaine-dependent individuals. Arch Gen Psychiatry 66:422-430.
11. Carrasco GA, Van de Kar LD, Sullivan NR, Landry M, Garcia F, Muma NA, Battaglia G. 2006. Cocaine-mediated supersensi-tivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience 143:7-13.
12. Centonze D, Napolitano M, Saulle E, Gubellini P, Picconi B, Martorana A, Pisani A, Gulino A, Bernardi G, Calabresi P. 2002. Tissue plasminogen activator is required for corticostriatal long-term potentiation. Eur J Neurosci 16:713-721. (Pubitemid 35471841)
13. Chomczynski P, Sacchi N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159.
14. Cleck JN, Ecke LE, Blendy JA. 2008. Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice. Psychopharmacology 201:15-28.
15. Gualandris A, Jones TE, Strickland S, Tsirka SE. 1996. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci 16:2220-2225.
16. Hashimoto T, Kajii Y, Nishikawa T. 1998. Psychotomimetic-induction of tissue plasminogen activator mRNA in corticos-triatal neurons in rat brain. Eur J Neurosci 10:3387-3399.
17. Iredale PA, Alvaro JD, Lee Y, Terwilliger R, Chen YL, Duman RS. 2000. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 74:199-208.
18. Jacobsen LK, Giedd JN, Kreek MJ, Gottschalk C, Kosten TR. 2001. Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary- adrenal axis function in cocaine depen dence: A preliminary report. Drug Alcohol Depend 62:49-56.
19. Koob GF. 2008. A role for brain stress systems in addiction. Neuron 59:11-34.
20. Koob GF, Kreek MJ. 2007. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 164:1149-1159.
21. Kreek MJ, Koob GF. 1998. Drug dependence: Stress and dysregulation of brain reward pathways. Drug Alcohol Depend 51:23-47.
22. Levy AD, Li Q, Alvarez Sanz MC, Rittenhouse PA, Kerr JE, Van de Kar LD. 1992. Neuroendocrine responses to cocaine do not exhibit sensitization following repeated cocaine exposure. Life Sci 51:887-897.
23. Maiya R, Zhou Y, Norris E, Kreek MJ, Strickland S. 2009. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci USA 106:1983-1988.
24. Mantsch JR, Taves S, Khan T, Katz ES, Sajan T, Tang LC, Cullinan WE, Ziegler DR. 2007. Restraint-induced corticoster-one secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration. Neurosci Lett 415:269-273.
25. Markou A, Kosten TR, Koob GF. 1998. Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18: 135-174.
26. Matys T, Pawlak R, Matys E, Pavlides C, McEwen BS, Strickland S. 2004. Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc Natl Acad Sci USA 101:16345-16350.
27. McNally GP, Akil H. 2002. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory and endocrine consequences of opiate withdrawal. Neuroscience 112:605-617.
28. Mendelson JH, Teoh SK, Mello NK, Ellingboe J, Rhoades E. 1992. Acute effects of cocaine on plasma adrenocorticotropic hormone, luteinizing hormone and prolactin levels in cocaine-dependent men. J Pharmacol Exp Ther 263:505-509.
29. Mendelson JH, Sholar M, Mello NK, Teoh SK, Sholar JW. 1998. Cocaine tolerance: Behavioral, cardiovascular, and neuroendo-crine function in men. Neuropsychopharmacology 18: 263-271.
30. Merlo Pich E, Lorang M, Yeganeh M, Rodriguez de Fonseca F, Raber J, Koob GF, Weiss F. 1995. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15: 5439-5447.
31. Miczek KA, Covington HE 3rd, Nikulina EM, Jr, Hammer RP. 2004. Aggression and defeat: Persistent effects on cocaine self-administration and gene expression in peptidergic and aminergic mesocorticolimbic circuits. Neurosci Biobehav Rev 27: 787-802.
32. Moldow RL, Fischman AJ. 1987. Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides 8: 819-822.
33. Nagai T, Yamada K, Yoshimura M, Ishikawa K, Miyamoto Y, Hashimoto K, Noda Y, Nitta A, Nabeshima T. 2004. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 101:3650-3655.
34. NicoleO,DocagneF, AliC,MargaillI,CarmelietP,MacKenzie ET, Vivien D, Buisson A. 2001. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7:59-64.
35. Norris EH, Strickland S. 2007. Modulation of NR2B-regulated contextual fear in the hippocampus by the tissue plasminogen activator system. Proc Natl Acad Sci USA 104:13473-13478.
36. Olive MF, Koenig HN, Nannini MA, Hodge CW. 2002. Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 72: 213-220.
37. Pawlak R, Magarinos AM, Melchor J, McEwen B, Strickland S. 2003. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci 6: 168-174.
38. Peltier RL, Guerin GF, Dorairaj N, Goeders NE. 2001. Effects of saline substitution on responding and plasma corticosterone in rats trained to self-administer different doses of cocaine. J Pharmacol Exp Ther 299:114-120.
39. Piazza PV, Le Moal M. 1997. Glucocorticoids as a biological substrate of reward: Physiological and pathophysiological implications. Brain Res Rev 25:359-372.
40. Richter RM, Weiss F. 1999. In vivo CRF release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 32:254-261.
41. Richter RM, Pich EM, Koob GF, Weiss F. 1995. Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from rat amygdala after repeated administration as determined by intracranial microdialysis. Neurosci Lett 187:169-172.
42. Ripley TL, Rocha BA, Oglesby MW, Stephens DN. 1999. Increased sensitivity to cocaine, and over-responding during cocaine self-administration in tPA knockout mice. Brain Res 826:117-127.
43. Rivier C, Vale W. 1987. Cocaine stimulates adrenocorticotropin (ACTH) secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain Res 422:403-406.
44. Rodriguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F. 1997. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 276: 2050-2054.
45. Rudoy CA, Reyes AR, Van Bockstaele EJ. 2009. Evidence for beta (1)-adrenergic receptor involvement in amygdalar corticotropin-releasing factor gene expression: Implications for cocaine withdrawal. Neuropsychopharmacology 34:1135-1148.
46. Samson AL, Medcalf RL. 2006. Tissue-type plasminogen activator: A multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 50:673-678.
47. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G. 1995. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 675: 89-97.
48. Sarnyai Z, Dhabhar FS, McEwen BS, Kreek MJ. 1998. Neuroendocrine-related effects of long-term, "binge" cocaine administration: Diminished individual differences in stress-induced corticosterone response. Neuroendocrinology 68: 334-344.
49. Sinha R, Talih M, Malison R, Cooney N, Anderson GM, Kreek MJ. 2003. Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology 170: 62-72.
50. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. 2006. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 63:324-331.
51. Smith RJ, Aston-Jones G. 2008. Noradrenergic transmission in the extended amygdala: Role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213: 43-61.
52. Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP, Koob GF. 2002. Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: Regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 26:1494-1501.
53. Vescovi PP, Coiro V, Volpi R, Passeri M. 1992. Diurnal variations in plasma ACTH, cortisol and beta-endorphin levels in cocaine addicts. Horm Res 37:221-224.
54. Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR. 2001. Compulsive drug-seeking behavior and relapse. Neuroadapta-tion, stress, and conditioning factors. Ann NY Acad Sci 937: 1-26.
55. Yamada K, Nagai T, Nabeshima T. 2005. Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci 97:157-161.
56. Yan Y, Yamada K, Mizoguchi H, Noda Y, Nagai T, Nitta A, Nabeshima T. 2007. Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice. Neuroscience 146:50-59.
57. Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ. 1996. Corticotropin-releasing factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"- pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 279:351-358.
58. Zhou Y, Spangler R, Ho A, Kreek MJ. 2003a. Increased CRH mRNA levels in the rat amygdala during short-term withdrawal from chronic "binge" cocaine. Mol Brain Res 114:73-79.
59. Zhou Y, Spangler R, Schlussman SD, Ho A, Kreek MJ. 2003b. Alterations in hypothalamic-pituitary-adrenal axis activity and in levels of proopiomelanocortin and corticotropin-releasing hormone-receptor 1 mRNAs in the pituitary and hypothalamus of the rat during chronic "binge" cocaine and withdrawal. Brain Res 964:187-199.
60. Zorrilla EP, Valdez GR, Weiss F. 2001. Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharma-cology 158:374-381.